Development of a PPAR/AMPK dual agonist for treatment of diabetes and metabolic syndrome

Seoul National University Hospital



METABOLIC	Lead
Product Type	Small molecule
Indication	Diabetes & Metabolic diseases
Target	PPAR, AMPK
MoA(Mechanism of Action)	Activating PPAR and AMPK by direct binding to PPAR and AMPK → improves insulin sensitivity
Competitiveness	 To show an additive effect as a PPAR/AMPK dual agonist Not to induce obesity through selective PPAR activation and/or AMPK activation To activate AMPK as a direct AMPK agonist
Development Stage	Lead
Route of Administration	Oral administration